David Mai,Carl H June,Neil C Sheppard
David Mai
Cancer is becoming increasingly understood not only as a disease of pathological cells but also as one of immune hypofunction. The heterogenous and patient-specific nature of cancer further underscores the need for personalized cellular the...
Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment [0.03%]
组合癌症免疫疗法：适应肿瘤微环境的新兴治疗方法
Nicole Kirchhammer,Marcel P Trefny,Priska Auf der Maur et al.
Nicole Kirchhammer et al.
Immune checkpoint blockade (ICB) has revolutionized cancer treatment. However, resistance to ICB occurs frequently due to tumor-intrinsic alterations or extrinsic factors in the tumor microenvironment. This Viewpoint aims to give an update ...
CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models [0.03%]
靶向CD22的CD28双特异性抗体提高难治性弥漫大B细胞淋巴瘤模型中odronextamab的抗肿瘤效能
Joyce Wei,Welby Montalvo-Ortiz,Lola Yu et al.
Joyce Wei et al.
Although many patients with diffuse large B cell lymphoma (DLBCL) may achieve a complete response to frontline chemoimmunotherapy, patients with relapsed/refractory disease typically have poor outcomes. Odronextamab, a CD20xCD3 bispecific a...
Miro E Raeber,Dilara Sahin,Onur Boyman
Miro E Raeber
Molecular insights into the mechanism of beneficial and adverse effects of interleukin-2 (IL-2) have resulted in the development of improved IL-2 formulations with IL-2 receptor bias and tissue-targeting properties. Several of these compoun...
BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion [0.03%]
转录因子 BLIMP1 和 NR4A3 互相对抗肿瘤CAR T细胞的干性和衰竭进行调节
In-Young Jung,Vivek Narayan,Sierra McDonald et al.
In-Young Jung et al.
Chimeric antigen receptor (CAR) T cells have not induced meaningful clinical responses in solid tumors. Loss of T cell stemness, poor expansion capacity, and exhaustion during prolonged tumor antigen exposure are major causes of CAR T cell ...
Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy [0.03%]
将肿瘤不断变化的分子图谱转化为癌症免疫治疗反应的生物标志物
Valsamo Anagnostou,Blair V Landon,Jamie E Medina et al.
Valsamo Anagnostou et al.
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapeutics, triggering studies to understand the molecular and cellular wiring of response and resistance. Our increased understanding of the underlying biology of response to...
Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies [0.03%]
CAR T细胞的汇集筛查鉴定出下一代免疫治疗中多样性的免疫信号域
Daniel B Goodman,Camillia S Azimi,Kendall Kearns et al.
Daniel B Goodman et al.
Chimeric antigen receptors (CARs) repurpose natural signaling components to retarget T cells to refractory cancers but have shown limited efficacy in persistent, recurrent malignancies. Here, we introduce "CAR Pooling," a multiplexed approa...
Swiss public health measures associated with reduced SARS-CoV-2 transmission using genome data [0.03%]
利用基因组数据发现瑞士公共卫生措施与降低SARS-CoV-2传播之间的关联
Sarah A Nadeau,Timothy G Vaughan,Christiane Beckmann et al.
Sarah A Nadeau et al.
Genome sequences from evolving infectious pathogens allow quantification of case introductions and local transmission dynamics. We sequenced 11,357 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomes from Switzerland in 202...
S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters [0.03%]
口服药物S-217622可抑制新冠病毒复制并改善hamsters的新冠肺炎症状
Michihito Sasaki,Koshiro Tabata,Mai Kishimoto et al.
Michihito Sasaki et al.
In parallel with vaccination, oral antiviral agents are highly anticipated to act as countermeasures for the treatment of the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2...
Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade [0.03%]
癌症糖基化的靶向治疗可重编程肿瘤相关巨噬细胞并实现有效的免疫检查点阻断疗法
Michal A Stanczak,Natalia Rodrigues Mantuano,Nicole Kirchhammer et al.
Michal A Stanczak et al.
Immune checkpoint blockade (ICB) has substantially improved the prognosis of patients with cancer, but the majority experiences limited benefit, supporting the need for new therapeutic approaches. Up-regulation of sialic acid-containing gly...